

Supplementary Material

1
2

Projection of number of infections and observation rate from assumed infection fatality ratio

Methods

3 Our data included reported cases and deaths for 3 Brazilian states: São Paulo (SP), Minas Gerais
4 (MG) and Rio de Janeiro (RJ). From the mortality time series (MTS), we projected the local number
5 of infections making two main simplifying assumptions: that the infection fatality ratio of SARS-
6 CoV-2 would be similar in Brazil to that reported elsewhere, and that the number of deaths is well
7 reported.

8
9
10
11
12 The infection fatality ratio (IFR) is calculated by the ratio of number of deaths and number of
13 infections, in which the latter is generally unknown and likely to be a few to several times higher
14 than reported cases. The IFR we consider is the one reported by Verity and colleagues (mean
15 0.66%, CI 95% 0.39-1.33%, [1]) for its general use in modelling aimed at informing interventions,
16 e.g. [2]. For each Brazilian state, using the mean and 95%CI of the IFR, we obtain a projected total
17 number of cases in time $I(t) = D(t) / (IFR / 100)$, where $D(t)$ is the cumulative number of deaths. With
18 a projection of the number of infections in time, we obtain the likely observation rate of cases from
19 $\theta(t) = c(t) / I(t)$ where $c(t)$ is the number of reported cases in time. We also looked at the case
20 fatality ratio (CFR) in time, defined as the ratio between the reported deaths and reported cases.

Results

21
22 The 3 Brazilian states presented the same general behaviour in terms of projected total number of
23 infections and reported cases: the difference between the number of projected total infections
24 (informed by the MTS) and the number of reported cases increased in time (Figure S1, top). As
25 such, the projected observation rates declined with time (Figure S1, bottom), and all states
26 appeared to converge to similar observation rates with time. By the last time point analysed, RJ
27 and SP had similar observation rates at 7.6% (4.49-15.3) for RJ and 7.74% (4.57-15.6) for SP.
28 MG, for which the epidemic has started later in time, the observation rate was 15.3% (9.05-30.8).




Figure S1. (top) Reported cumulative cases (black) and projected number of infections (colors) per state. (bottom) Projected observation rate per state. SP = São Paulo, MG = Minas Gerais, RJ = Rio de Janeiro.

29

30 We next looked at the CFR within the states (Figure S2). Following the trend in decreasing
 31 observation rates, the CRF increased with time. RJ and SP presented similar CRF at the end of the
 32 time series data (which had similar lengths), while MG consistently presented lower CRF than the
 33 other two states. The CRFs for the entire period were: 2.67% (0.63-4.04) for MG, 5.39% (1.71-9.0)
 34 for RJ and 6.0% (1.66-8.4) for SP. For SP and RJ, these were consistently higher than reported
 35 elsewhere, e.g.: 2.6% (95% CI 0.89-6.7) for the Diamond Princess cruise ship [3], and 3.67% (95%
 36 CI 3.56-3.80) and 1.2% (95% CI 0.3-2.7) and 1.4% (95% CI 0.9-2.1) for Wuhan (China) [1,3,4].

37

38




Figure S2. (A, left) Case fatality ratio in time for each state. (B, right) Case fatality ratio (mean, 95% range) for entire period of data (full circles) and for the last 10 days of each time series (open diamonds). SP = São Paulo, MG = Minas Gerais, RJ = Rio de Janeiro.

39

40 Estimation of reproduction numbers

41

42 The reproduction number R (basic R_0 , effective R_e) of a pathogen can be estimated using
 43 mechanistic or statistical models applied to time series of confirmed cases. At early stages of an
 44 outbreak, methods aim at fitting the epidemic growth rate r , from which estimates of doubling
 45 times, R_0 and R_e can be obtained under certain assumptions.

46

47 For SARS-CoV-2 the confirmed (cases) time series (CTS) are subject to many undetermined
 48 factors. For example, test results depend on time since infection and sample type. At the start of
 49 the epidemic testing also tends to be reserved for contact tracing, and unless all cases are traced,
 50 it is thus a biased sample of ongoing transmission. The latter is a particularly problematic factor,
 51 since the vast majority of SARS-CoV-2 infections are known to be asymptomatic. Depending on
 52 local capacity and infrastructure, testing efforts may not be constant in time. In fact, as the
 53 epidemic progresses, testing capacity may be overwhelmed, or testing strategies may shift to
 54 target particular subgroups of the population.

55

56 For SARS-CoV-2, a second epidemic data source is the mortality time series. Here, we assume
 57 that death events (and thus MTS) are less prone to problems such as those that affect the
 58 representativeness of CTS versus the real but unknown infection time series (ITS). In particular,
 59 that death events should be more easily detected, since they only occur in symptomatic infections,
 60 they do not necessarily depend on the frailties of tests for current infection, and reporting of all
 61 death events in a community is generally mandatory and performed on already existing pathways
 62 in health systems. Deaths mostly occur among a proportion of the population at risk of severe
 63 disease [5]. A potentially long time period between infection and death has also been reported [6].
 64 The MTS is expected to be both a lagged and undersampling of the ITS. Most importantly for the

65 estimation of the epidemic growth rate, we here assume that the MTS should conserve the growth
66 and shape of the unknown ITS.

67
68 In this supplementary material, we estimate the epidemic growth rate r of the ITS from the CTS
69 and from the MTS independently. We use a maximum likelihood estimation approach together with
70 a phenomenological model of exponential growth, and some well established theoretical
71 formulations on how r relates to R . For the estimations based on MTS data, we include 3 Brazilian
72 states - São Paulo (SP), Rio de Janeiro (RJ), Minas Gerais (MG) - and for comparison, also
73 include MTS from the United Kingdom (UK), Italy (IT) and Spain (SN). For the estimations based
74 on the CTS data, we include the 3 Brazilian states only.

75 **Methods**

76 **Phenomenological model**

77 We used the model described in [7]: $M(t) = A t^m$, where $M(t)$ is the number of cumulative deaths in
78 time t , m is a positive integer, $m = 1/(1 - p)$, $A = M_0^{1/m}$ with M_0 the number of deaths at $t=0$, and p is
79 the deceleration of growth parameter. The later exists in $0 < p < 1$, for which sub-exponential growth
80 is obtained. For example, for $p=0.5$ growth is quadratic, and as $p \rightarrow 1$ growth will tend to be purely
81 exponential in the limit. We use this general formulation (instead of pure exponential formulation) to
82 allow for further flexibility in future research. For the results presented, we assume growth is
83 exponential, fixing p to 0.9999.

84

85 **Maximum likelihood estimation of growth rate**

86 Cumulative death counts are modelled according to the phenomenological model detailed above,
87 and the negative log-likelihood of the data given the model is defined using a negative-binomial
88 distribution. The function `mle2` from the R-package `bbmle` was used to estimate the growth rate r
89 with default parameters and method set as 'Brent' (for one dimensional MLE) [8]

90

91 **Relationship of growth rate r with reproduction number R**

92 The reproduction number R was estimated from the maximum likelihood estimated growth rate r in
93 two different ways:

94

95 (i) The estimated growth rate r and an assumed serial interval distribution (SID) were used to
96 calculate $R = \hat{r}$ with $a = m^2/s^2$ and $b = m/s^2$, m being the SID mean and s the SID standard
97 deviation. This approach is similar to that described in Imperial College London's report 13 (ICL13)
98 [2]. In this approach, no assumptions are made on the infectious, latent or incubation periods of
99 SARS-CoV-2. The SID distribution used is the one estimated by Nishiura and colleagues [9], with
100 $m=4.7$ and $s=2.9$ (also very similar to the ones used in [2,10]). We term this approach the serial
101 interval approach.

102

103 (ii) The estimated growth rate r and assumed prior distributions for the incubation and infectious
104 periods of SARS-CoV-2 were used to calculate $R = (1+r/\sigma)(1+r/\delta)$, with $1/\sigma$ the infectious period

105 (InfP) and $1/\delta$ the incubation period (IncP). This approach is the one described by Wallinga and
106 Lipsitch [11], which is based on an SEIR modelling framework and expects both the InfP and IncP
107 to be exponentially distributed. We assumed priors with exponential distributions with mean 5.1
108 days for IncP [2,6,12–17] and 4 days for the InfP [6,12,13,16]. We term this approach the SEIR
109 estimation.
110

111 Doubling time, geographical distances and population size

112 Doubling time was calculated as $\ln(2)/r$ with r the growth rate [11]. Geographical distances (lat,lon)
113 between death / case reports were calculated using the function *distVincentyEllipsoid* from the R-
114 package *geosphere* R-package [5,18]. We considered the approximate population sizes 40M for
115 SP, 16.5M for RJ, 21M for MG, 66M for UK, 60M for IT and 47 for SN.

116 Reproduction number results using the case time series (CTS)

117 Each of the 3 Brazilian states had CTS of different length (here starting on the date of the first
118 reported case), and the growth rate appeared to vary in time within each state (Figure S3). Slowing
119 down of the CTS has been described in many regions and is likely to be a consequence of
120 changes in population behaviour and / or official social distancing interventions [13,15,19].
121




Figure S3.

Log10 cumulative cases per Brazilian state and European country (coloured diamonds).

SP = São Paulo, MG = Minas Gerais, RJ = Rio de Janeiro.

122 We divided the CTS of each state into several periods (according to total size) and performed the
123 MLE of growth rate independently for those periods (MG: 4, RJ: 4, SP:5 equally spaced periods). A
124 summary of the resulting fits is presented in Figure S4. The phenomenological model was able to
125 approximate the CTS of each state (white points for data versus colored diamonds for model). As
126 the CTS of all states slowed down with time, the mean estimated R also slowed down with time.
127
128




Figure S4.

Log10 cumulative cases per Brazilian state (white points) versus mean model fit (colored diamonds).

Colored line segments are the estimated R mean for each of the considered time periods per state (colors).

Horizontal dotted line is $R=1$.

SP = São Paulo, MG = Minas Gerais, RJ = Rio de Janeiro.

129

130 The posteriors for doubling times and R (from the SEIR approach) per time period are presented in
 131 Figure S5. Following the slow down of the CTS of each state, the doubling time increases and the
 132 R decreases with time. The doubling time posteriors present little variation, related only to the MLE
 133 estimated growth rate r . The R estimations present more variation, both from the MLE estimated
 134 growth rate r as well as from the sampling of the assumed priors for the incubation and infectious
 135 periods (described for the SEIR approach above).

136




Figure S5. (A, left) Doubling times as estimated for each state / country per considered time period. (B, right) R as estimated for each state per considered time period (SEIR approach). SP = São Paulo, MG = Minas Gerais, RJ = Rio de Janeiro.

137

138 We also looked at a posterior of R across the different fitted periods per region, by considering all
 139 of the posteriors from each period (Figure S6). The two methods of estimating R from the growth
 140 rate gave similar posteriors (albeit with different variation). For the SEIR approach, the estimates
 141 were: SP 2.07 (CI 95% 1.01-4.1); RJ 2.3 (CI 95% 1.02-4.0); and MG 1.9 (CI 95% 1.01-3.7). For the
 142 serial interval approach, the estimates were: SP 1.91 (CI 95% 1.2-3.1); RJ 1.88 (CI 95% 1.27-2.8);

143 and MG 1.82 (CI 95% 1.2-3.25). These R ranges are similar between approaches and to others
 144 reported elsewhere after lockdown interventions [12,16,20,21]. The first estimation for each state
 145 was higher, likely a representation of lower adherence or lack of lockdown guidelines initially, and
 146 importantly also in range with previously reported estimates on pre-lockdown [13][22][23] [20][24].
 147




Figure S6. (A, left) R as estimated for each state / country for their entire CTS (SEIR approach). (B, right) R as estimated for each state / country for their entire CTS (serial interval approach). SP = São Paulo, MG = Minas Gerais, RJ = Rio de Janeiro.

148
 149 Incidence is typically calculated per 100K individuals ($inc = 100K * cases / population\ size$).
 150 However, the denominator in the normalisation (state population size) may not be representative of
 151 the total population affected by the virus in the Brazillian states. In other words, a more
 152 representative denominator could be the total population size of only the areas (within each state)
 153 that have had reported cases. We termed this population size the effective population size of each
 154 state - which was ~16.5M for RJ, ~40M for SP and ~13.6M for MG. In relation to the total
 155 population sizes of the states, this equated to ~100% of RJ, ~100% of SP and 64% of MG. When
 156 normalizing the CTS per 100K using the effective population sizes, the CTS for SP and RJ
 157 remained largely unchanged, but the CTS for MG was transformed to higher values (Figure S7).
 158 Thus, by 28/04/2020, using the effective population sizes, we calculate that the case incidence per
 159 100K has been ~60 in SP, ~51 in RJ and ~7.85 in MG.
 160




Figure S7. (A, left) Cumulative cases per effective 100K individuals per state / country with normalised time to day of first reported case and normalised to the maximum number of cases per CTS. See definition of effective population size in the text. (B, right) Same as A but zoomed in for the first 30 days. SP = São Paulo, MG = Minas Gerais, RJ = Rio de Janeiro. See main text for data sources.

161 **Reproduction number results using the mortality time series (MTS)**

162 Each of the MTS analysed had different lengths (here starting on the date of first death) (Figure
 163 S8). We thus divided the MTS into several periods and performed the MLE of growth rate
 164 independently for those periods (MG: 4, RJ: 4, SP:6, UK:7, SN:5 equally spaced periods). A
 165 summary of the resulting fits is presented in Figure S9. The phenomenological model is able to
 166 approximate the MTS of each state (white points for data versus colored diamonds for model). As
 167 the MTS of all states slowed down with time, the mean estimated R also slowed down.
 168




Figure S8.

Log10 cumulative deaths per Brazilian state and European country (coloured diamonds).

SP = São Paulo, MG = Minas Gerais, RJ = Rio de Janeiro, IT = Italy, UK = United Kingdom and SN = Spain.

See main text for data sources.

169




Figure S9.

Log10 cumulative deaths per Brazilian state (white points) versus mean model fit (colored diamonds).

Colored line segments are the estimated R mean for each of the considered time periods per state (colors).

Horizontal dotted line is R=1.

SP = São Paulo, MG = Minas Gerais, RJ = Rio de Janeiro.

See main text for data sources.

170 The posteriors for doubling times and R (from the SEIR approach) per time period are presented in
 171 Figure S10. Following the slow down of the MTS of each state, the doubling time increases and the
 172 R decreases with time. The doubling time posteriors present little variation, related only to the MLE
 173 estimated growth rate r.
 174




Figure S10. (A, left) Doubling times as estimated for each state / country per considered time period. (B, right) R as estimated for each state per considered time period (SEIR approach). SP = São Paulo, MG = Minas Gerais, RJ = Rio de Janeiro, IT = Italy, UK = United Kingdom and SN = Spain.

175
 176 The posterior of R across the different fitted periods per state are presented in Figure S11. The two
 177 methods of estimating R from the growth rate gave similar posteriors. For the SEIR approach, the
 178 estimates were: SP 2.32 (CI 95% 1.01-4.5); RJ 1.84 (CI 95% 1.01-3.66); and MG 1.74 (CI 95%
 179 1.01-3.76). For the serial interval approach, the estimates were: SP 2.12 (CI 95% 1.3-5.2); RJ 1.75
 180 (CI 95% 1.27-2.26); and MG 1.8 (CI 95% 1.26-3.03). These R ranges are similar to the ones
 181 obtained from the CTS and others reported elsewhere (see list of citations above in the section
 182 dedicated to R estimation from CTS).




Figure S11. (A, left) R as estimated for each state / country for their entire MTS (SEIR approach). (B, right) R as estimated for each state / country for their entire MTS (serial interval approach). SP = São Paulo, MG = Minas Gerais, RJ = Rio de Janeiro, IT = Italy, UK = United Kingdom and SN = Spain.

183
 184 The effective population size of each state was 15.724.804 for RJ, 36.815.327 for SP and
 185 7.486.968 for MG. In relation to the total population sizes of the states, this equated to ~95% of RJ,
 186 ~92% of SP and 35% of MG. When normalizing the MTS per 100K using the effective population
 187 sizes, the MTS for SP and RJ remained largely unchanged, but the MTS for MG was transformed
 188 to become similar to the other states (Figure S12). Thus, by 28/04/2020, using the effective
 189 population sizes, we calculate that the mortality incidence per 100K has been ~5.56 in SP, ~4.69 in
 190 RJ and ~0.94 in MG.
 191




Figure S12. (A, left) Cumulative deaths per effective 100K individuals per state / country with normalised time to day of first reported death and normalised to the maximum number of deaths per MTS. See definition of effective population size in the text. (B, right) Same as A but zoomed in for the first 30 days. SP = São Paulo, MG = Minas Gerais, RJ = Rio de Janeiro. See main text for data sources.

192

193 **Spatial results**

194 **Methods: geographical distances and population size**

195 Geographical distances (lat,lon) between death / case reports were calculated using the function
196 *distVincentyEllipsoid* from the R-package *geosphere* R-package [5,18]. We considered the
197 approximate population sizes 40M for SP, 16.5M for RJ, 21M for MG, 66M for UK, 60M for IT and
198 47 for SN.

199 **Results using the mortality time series (CTS)**

200 We mapped the reported cases within the Brazilian states (Figure S13). In contrast to SP and RJ,
201 there appeared to be no clear signal around the capital city of MG (Belo Horizonte). This
202 suggested that the cases in MG were more uniformly distributed in the state, compared to the other
203 two states. The geo-location of each reported case was used to calculate the (pairwise) distance
204 (km) distribution of all cases (Figure S14A). Cases in the MG were on average ~271 km away,
205 ~104 in RJ and ~207 in SP. Differences between the distributions were significant with a Wilcox
206 test. We also calculated the distribution of distances between the location of each case and the
207 location of the capital city for each state (Figure S14B). In MG, reported deaths were on average
208 ~103 km from the capital Belo Horizonte, while in SP they were ~0.05 km, and in RJ ~1.45 km
209 away from their capital cities.
210




Figure S13. Map with location (município) of cases, colored by total number of reports.

Different background colors highlight the boundaries of the 3 states: blue for SP = São Paulo, red for MG = Minas Gerais, green for RJ = Rio de Janeiro.

211




Figure S14. (A, left) Distribution of distances between each pair of reported cases by state. (B, right) Distribution of distances between each reported case and each state's capital. 3 states: blue for SP = São Paulo, red for MG = Minas Gerais, green for RJ = Rio de Janeiro.

212 **Results using the mortality time series (MTS)**

213 The geographical distribution of reported deaths within the Brazilian states is presented in Figure
 214 S15. The distribution suggested that the cases in MG were more uniformly distributed in the state,
 215 compared to the other two states which appeared to have a higher number of cases close to their
 216 capital cities. The geo-location of each reported death was used to calculate the (pairwise)
 217 distance (km) distribution of all deaths (Figure S16A). Deaths in the MG were on average ~316 km
 218 away, ~86 in RJ and ~159 in SP. Differences between the distributions were significant with a
 219 Wilcoxon test. The distribution of distances between the location of each death event and the location
 220 of the capital city for each state (Figure S16B) also varied between states: in MG, reported deaths
 221 were on average ~229 km from the capital Belo Horizonte, while in SP they were ~28 km, and in
 222 RJ ~18 km away from their capital cities.
 223




Figure S15. Map with location (município) of death events, colored by total number of reports.

Different background colors highlight the boundaries of the 3 states: blue for SP = São Paulo, red for MG = Minas Gerais, green for RJ = Rio de Janeiro.

224





Figure S16. (A, left) Distribution of distances between each pair of reported deaths by state. (B, right) Distribution of distances between each reported death and each state's capital. 3 states: blue for SP = São Paulo, red for MG = Minas Gerais, green for RJ = Rio de Janeiro.

225
226



227

S17 Fig. Comparisons between demographic variables and Ct values from sequenced samples. (top-left) Age of sample individuals versus gender. (top-right) Cycle threshold (Ct) for age groups <65 and >=65 years of age. (bottom-left) Ct for gender. (bottom-right) Ct for age groups <50 and >=50 years of age. Wilcoxon p-value is presented for every panel. None of the comparisons are statistically significant.

232

233

234

235

236

237 **Other material**

238

239 **S1 Table.** Sequencing statistics for the 40 SARS-CoV-2 sequences generated.

Project-ID	Lab ID	Number Reads	Coverage (%)	Coverage depth	NT (%)	AA (%)
CV1	47/20	38727	74.8	900.2	99.3	98.7
CV2	115/20	4355	93.3	91.5	97.3	94.9
CV3	135/20	709	85.2	32.2	97.7	95.6
CV4	242/20	701399	99.8	12199.7	99.9	99.8
CV5	252/20	51430	50.4	1779.2	99	97.7
CV6	298/20	886430	99.7	16407.7	99.8	99.6
CV7	352/20	128770	77.8	2851.1	99	98.3
CV8	399/20	394793	97.1	7225.1	99.5	99.1
CV9	428/20	25233	90	1352.2	98.4	96.9
CV11	607/20	151738	68.4	7436	98.8	98
CV12	615/20	250223	94.4	4613.1	99.3	99
CV13	660/20	269275	94	5721.7	99.3	98.9
CV16	791/20	714787	99.3	12517.7	99.8	99.7
CV17	809/20	253298	83.8	5328	99.2	98.6
CV18	833/20	94542	68.4	2383.6	98.8	97.7
CV19	836/20	297994	93.7	5630	99.1	98.6
CV20	838/20	175601	84.8	3603.1	98.8	97.8
CV21	842/20	759661	99.8	13968.4	99.9	99.8
CV22	895/20	120293	74.4	3051.8	98.9	97.9
CV24	1028/20	164278	77.2	3242.2	98.8	98
CV26	1078/20	543415	98.2	9570.9	99.5	99.1
CV27	1166/20	92936	81.1	1653.1	99.8	99.5
CV28	1142/20	108547	88.8	1841.2	99.4	98.8
CV31	1274/20	724502	99.8	11455	99.9	99.8
CV32	1290/20	840747	99.8	14924.3	99.9	99.8
CV33	1420/20	240018	95.8	4396	99.8	99.6
CV34	1467/20	2636	75	45.7	96.8	93.5
CV35	1500/20	4002	82.8	81.9	97.8	95.8
CV36	1504/20	19333	49.9	558.2	99.9	99.2
CV40	1834/20	43159	55.7	1266.7	99.8	99.2
CV41	1892/20	140516	70.1	2680	99.7	99.2
CV42	2119/20	819943	99.2	13993.2	99.8	99.7
CV43	2159/20	319317	91	5364	99.7	99.4
CV44	2196/20	36069	68.3	761.5	99.6	99.0
CV45	2241/20	87213	73	1916.8	99.8	99.3
CV46	2271/20	26075	58	770.7	99.9	99.5
CV47	2288/20	46863	71.4	970.3	99.7	99.1
CV48	2693/20	173017	90.6	3291.5	99.8	99.5
CV49	2801/20	425400	95.5	8121.3	99.8	99.6

240 Project-ID=sample identifier; Coverage (%) = percentage of genome coverage relative to the reference *NC_045512.3*;
 241 NT (%) = percentage of nucleotide identity; AA (%) = percentage of amino acid identity.


242
 243
 244
 245

246 **S2 Table. Results from the lineage assessment.** The 40 new sequences from Minas Gerais were assessed by
 247 pipeline named Phylogenetic Assignment of Named Global Outbreak LINEages available in github.
 248

Taxon	Lineage	UFbootstrap
CV1_SARS-COV-2 Brazil MinasGerais Ipatinga 2020-03-04	B.1.8	45
CV2_BC02_SARS-COV-2 Brazil MinasGerais SeteLagoas 2020-03-08	B.1	82
CV3_BC03_SARS-COV-2 MinasGerais BeloHorizonte 2020-03-09	B.1	95
CV4_BC04_SARS-COV-2 Brazil MinasGerais JuizdeFora 2020-03-09	B.1	94
CV5_BC05_SARS-COV-2 Brazil MinasGerais BeloHorizonte 2020-03-12	B	72
CV6_BC06_SARS-COV-2 Brazil MinasGerais BeloHorizonte 2020-03-13	B.1	80
CV7_BC07_SARS-COV-2 Brazil MinasGerais BeloHorizonte 2020-03-13	A	81
CV8_BC08_SARS-COV-2 Brazil MinasGerais BeloHorizonte 2020-03-13	B.1	76
CV9_BC09_SARS-COV-2 Brazil MinasGerais BeloHorizonte 2020-03-13	B	81
CV11_BC10_SARS-COV-2 Brazil MinasGerais Mariana 2020-03-16	B	89
CV12_BC11_SARS-COV-2 Brazil MinasGerais JuizdeFora 2020-03-11	B.1	74
CV13_BC12_SARS-COV-2 Brazil MinasGerais BeloHorizonte 2020-03-15	B.1	96
CV16_BC13_SARS-COV-2 Brazil MinasGerais BeloHorizonte 2020-03-16	B.1	76
CV17_BC14_SARS-COV-2 Brazil MinasGerais SeteLagoas 2020-03-11	B.1	83
CV18_BC15_SARS-COV-2 Brazil MinasGerais BeloHorizonte 2020-03-16	B.1	97
CV19_BC16_SARS-COV-2 Brazil MinasGerais BeloHorizonte 2020-03-16	B.1	69
CV20_BC17_SARS-COV-2 Brazil MinasGerais BeloHorizonte 2020-03-16	B.1	94
CV21_BC18_SARS-COV-2 Brazil MinasGerais BomDespacho 2020-03-16	B.1	82
CV22_BC19_SARS-COV-2 Brazil MinasGerais Mariana 2020-03-16	B.2	45
CV24_BC20_SARS-COV-2 Brazil MinasGerais Uberlandia 2020-03-16	B.1	98
CV26_BC22_SARS-COV-2 Brazil MinasGerais BeloHorizonte 2020-03-17	B.1	84
CV27 SARS-COV-2 Brazil MinasGerais BoaEsperanca 2020-03-17	B.1	100
CV28_BC24_SARS-COV-2 Brazil MinasGerais SaoJoaodelRei 2020-03-17	B.1	20
CV31 SARS-COV-2 Brazil MinasGerais Betim 2020-03-17	B.1.5	75
CV32 SARS-COV-2 Brazil MinasGerais Betim 2020-03-17	B.1	84
CV33 SARS-COV-2 Brazil MinasGerais Sabara 2020-03-17	B.1	72
CV34 SARS-COV-2 Brazil MinasGerais BeloHorizonte 2020-03-16	B.1	98
CV35 SARS-COV-2 Brazil MinasGerais PocosDeCaldas 2020-03-18	B.1	99
CV36 SARS-COV-2 Brazil MinasGerais Muriae 2020-03-18	B.2	46
CV40 SARS-COV-2 Brazil MinasGerais BeloHorizonte 2020-03-19	B.1	99
CV41 SARS-COV-2 Brazil MinasGerais SerraDoSalitre 2020-03-18	B.1	85
CV42 SARS-COV-2 Brazil MinasGerais SaoJoaoDelRei 2020-03-20	B.1	97
CV43 SARS-COV-2 Brazil MinasGerais Patrocinio 2020-03-17	B.1	73
CV44 SARS-COV-2 Brazil MinasGerais Patrocinio 2020-03-18	B.1	75

CV45 SARS-COV-2 Brazil MinasGerai Muriae 2020-03-20	B.1	99
CV46 SARS-COV-2 Brazil MinasGerai BeloHorizonte 2020-03-20	B.1	100
CV47 SARS-COV-2 Brazil MinasGerai BeloHorizonte 2020-03-19	B.1	99
CV48 SARS-COV-2 Brazil MinasGerai Varginha 2020-03-20	B.1	84
CV49 SARS-COV-2 Brazil MinasGerai BeloHorizonte 2020-03-20	B.1	66
CV50 SARS-COV-2 Brazil MinasGerai Mariana 2020-03-26	B.1	95

249



251 **Figure S18.** A regression of genetic divergence from root to tip against sampling dates using TemEst for each sub-
 252 dataset analysed in BEAST.

253

254

References

- 256 1. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity
257 of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis.* 2020.
258 doi:10.1016/S1473-3099(20)30243-7
- 259 2. Flaxman S. Estimating the number of infections and the impact of non- pharmaceutical
260 interventions on COVID-19 in 11 European countries. Imperial College COVID-19 Response
261 Team. 2020. Available: [https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/
262 gida-fellowships/Imperial-College-COVID19-Europe-estimates-and-NPI-impact-30-03-2020.pdf](https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-Europe-estimates-and-NPI-impact-30-03-2020.pdf)
- 263 3. Russell TW, Hellewell J, Jarvis CI, van Zandvoort K, Abbott S, Ratnayake R, et al. Estimating
264 the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted
265 data from the outbreak on the Diamond Princess cruise ship, February 2020. *Euro Surveill.*
266 2020;25. doi:10.2807/1560-7917.ES.2020.25.12.2000256
- 267 4. Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, et al. Estimating clinical
268 severity of COVID-19 from the transmission dynamics in Wuhan, China. *Nat Med.* 2020;26:
269 506–510.
- 270 5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of
271 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.*
272 2020;395: 1054–1062.
- 273 6. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung S-M, et al. Incubation
274 Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with
275 Right Truncation: A Statistical Analysis of Publicly Available Case Data. *J Clin Med Res.*
276 2020;9. doi:10.3390/jcm9020538
- 277 7. Chowell G, Sattenspiel L, Bansal S, Viboud C. Mathematical models to characterize early
278 epidemic growth: A review. *Phys Life Rev.* 2016;18: 66–97.
- 279 8. bbmle R-package V1.0.23.1. Available:
280 <https://cran.r-project.org/web/packages/bbmle/index.html>
- 281 9. Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus (COVID-19)
282 infections. *Int J Infect Dis.* 2020;93: 284–286.
- 283 10. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding
284 and transmissibility of COVID-19. *Nat Med.* 2020. doi:10.1038/s41591-020-0869-5
- 285 11. Wallinga J, Lipsitch M. How generation intervals shape the relationship between growth rates
286 and reproductive numbers. *Proc Biol Sci.* 2007;274: 599–604.
- 287 12. Kucharski AJ, Russell TW, Diamond C, Liu Y, Edmunds J, Funk S, et al. Early dynamics of
288 transmission and control of COVID-19: a mathematical modelling study. *Lancet Infect Dis.*
289 2020. doi:10.1016/S1473-3099(20)30144-4
- 290 13. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan,
291 China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med.* 2020.
292 doi:10.1056/NEJMoa2001316
- 293 14. Woelfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Mueller MA, et al. Clinical

- 294 presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in
295 a travel-associated transmission cluster. doi:10.1101/2020.03.05.20030502
- 296 15. Salje H, Kiem CT, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden
297 of SARS-CoV-2 in France. doi:10.1101/2020.04.20.20072413
- 298 16. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection
299 facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). *Science*. 2020.
300 doi:10.1126/science.abb3221
- 301 17. Davies NG, Klepac P, Liu Y, Prem K, Jit M, Eggo RM, et al. Age-dependent effects in the
302 transmission and control of COVID-19 epidemics. doi:10.1101/2020.03.24.20043018
- 303 18. geosphere R-package 1.5-10. Available:
304 <https://cran.r-project.org/web/packages/geosphere/index.html>
- 305 19. Tian H, Liu Y, Li Y, Wu C-H, Chen B, Kraemer MUG, et al. The impact of transmission control
306 measures during the first 50 days of the COVID-19 epidemic in China.
307 doi:10.1101/2020.01.30.20019844
- 308 20. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and
309 international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling
310 study. *The Lancet*. 2020. pp. 689–697. doi:10.1016/s0140-6736(20)30260-9
- 311 21. Tindale L, Coombe M, Stockdale JE, Garlock E, Lau WYV, Saraswat M, et al. Transmission
312 interval estimates suggest pre-symptomatic spread of COVID-19.
313 doi:10.1101/2020.03.03.20029983
- 314 22. Tang B, Wang X, Li Q, Bragazzi NL, Tang S, Xiao Y, et al. Estimation of the Transmission
315 Risk of 2019-nCoV and Its Implication for Public Health Interventions. *SSRN Electronic
316 Journal*. doi:10.2139/ssrn.3525558
- 317 23. Cao Z, Zhang Q, Lu X, Pfeiffer D, Jia Z, Song H, et al. Estimating the effective reproduction
318 number of the 2019-nCoV in China. doi:10.1101/2020.01.27.20018952
- 319 24. Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W, et al. Preliminary estimation of the basic
320 reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-
321 driven analysis in the early phase of the outbreak. *Int J Infect Dis*. 2020;92: 214–217.

322